Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ: BIAFW )

0.4825 +0.0525 (+12.21%)
Streaming Delayed Price Updated: 1:40 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about bioAffinity Technologies, Inc. - Warrant

< Previous 1 2 Next >
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Set for Continued Expansion in 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies In The News
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies In the News
From bioAffinity Technologies
Via Business Wire
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
From bioAffinity Technologies, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.